Every Baby a Genome: How Newborn Sequencing Is Reinventing Precision Medicine

In October 2024, a team at Columbia University Irving Medical Center and NewYork-Presbyterian quietly published a result in JAMA that should have rearranged how American pediatrics thinks about the first week of life. Among the first 4,000 babies enrolled in the GUARDIAN study, supplemental genome sequencing identified 120 children with serious genetic conditions. Standard newborn screening, the heel prick blood spot test used in every state, had caught only 10 of them. Twelve times the detection rate, for diseases where early intervention is the difference between a life and a tragedy. For one infant, sequencing revealed a severe combined immunodeficiency that the conventional panel missed entirely. The finding triggered a bone marrow transplant. The child is alive.

Presented By Our Partners

That study is now one of five large, parallel initiatives running in 2026 that together represent the most consequential expansion of newborn screening since blood spot panels were standardized in the 1960s. GUARDIAN at NewYork-Presbyterian, BabySeq2 at Brigham and Women’s, BeginNGS at Rady Children’s in San Diego, the Generation Study across the NHS in England, and now BEACONS, the first multi-state public health pilot in the United States, funded with a $14.4 million NIH Common Fund award announced in January 2026. The era of every baby a genome has begun. The question is no longer whether whole genome sequencing will be added to the universal panel offered at birth, but on what timeline, with what guardrails, and at what cost.

What Standard Newborn Screening Actually Does

To understand why this matters, it helps to remember what the current panel is. Every baby born in the United States is screened, usually between 24 and 48 hours of life, with a small blood sample collected on a paper card and analyzed for a defined set of conditions chosen by each state. The federal Recommended Uniform Screening Panel currently lists 38 core conditions and 26 secondary conditions, ranging from phenylketonuria (PKU) and congenital hypothyroidism to cystic fibrosis, sickle cell disease, and severe combined immunodeficiency (SCID). The screen uses tandem mass spectrometry, immunoassays, and biochemical markers to flag babies who need confirmatory testing. It catches roughly one affected child for every 800 to 1,000 screened, and it has been one of the most cost-effective public health programs in the history of American medicine.

But conventional screening has a structural ceiling. It can only detect conditions that produce a measurable biochemical signal in the first few days of life. Diseases with delayed onset, conditions with variable biomarker expression, and disorders without a clean analyte signature all slip through. Many treatable monogenic disorders, including several inborn errors of immunity, lysosomal storage diseases, and severe early onset epilepsies, were either invisible to biochemistry or required confirmatory genetic testing after a clinical presentation that often came too late.

DNA sequencing, by contrast, can read the underlying instruction set directly. If a baby carries a pathogenic variant in a gene known to cause a treatable childhood disease, sequencing can identify it before symptoms appear. That capability is what the new studies are now testing at scale.

GUARDIAN: The Twelvefold Signal

The Genomic Uniform-screening Against Rare Disease in All Newborns study, GUARDIAN, is the largest American clinical evidence base to date. Led by principal investigator Wendy Chung and colleagues, the trial was launched in September 2022 at NewYork-Presbyterian hospitals in upper Manhattan and has now enrolled tens of thousands of newborns toward a target of 100,000. The first 4,000 results, published in JAMA on October 24, 2024 by Ziegler and colleagues, used genome sequencing to screen for 156 rare but treatable conditions, with an optional add-on panel of 99 untreatable conditions for which early intervention might still help.

The headline number, 120 babies with a serious genetic condition out of 4,000, is a 3 percent positive rate. Of those, 110 would have been missed by the standard panel. A substantial share of the variants identified were in disorders related to immune function, metabolism, or seizure prone epilepsy syndromes. For at least one family, the screening was directly lifesaving. The consent rate among parents offered the study was 72 percent, an unusually high figure for a research protocol and a signal that families value the information enough to opt in.

GUARDIAN also surfaced the practical infrastructure questions that will shape the next phase. Most positive results required follow up confirmatory testing, specialist evaluation, and genetic counseling. The team built dedicated counseling capacity and a return of results pathway that did not exist in standard neonatal care. Scaling that capacity nationally will be one of the central operational problems of the next decade.

BEACONS: The First Multi-State Public Health Pilot

If GUARDIAN is the proof of clinical value, BEACONS is the proof of public health feasibility. Announced in late 2025 and formally selecting its sites in January 2026, the Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening initiative is a $14.4 million NIH Common Fund Venture Program project led by Mass General Brigham and Ariadne Labs, with Boston Children’s Hospital, Albert Einstein College of Medicine, Case Western Reserve University, Baylor College of Medicine, the Association of Public Health Laboratories, GeneDx, and Illumina as partners.

BEACONS will enroll up to 30,000 newborns across six states and one territory: Iowa, Minnesota, New York, Oregon, South Carolina, Texas, and Puerto Rico. The crucial design choice is that BEACONS will pipe sequencing through existing state public health newborn screening programs, not through specialty academic centers. That difference matters because state programs are the only existing system in American medicine that comes close to universal coverage of a clinical intervention. Roughly 98 percent of American babies are screened through them today. If sequencing can be added to that pipeline, the path to universality is short. If it cannot, the path is long.

The BEACONS gene panel, finalized in January 2026, was curated through an explicit process of evidence weighting led by Robert Green of Mass General Brigham and Aaron Goldenberg of Case Western Reserve. The panel privileges genes for which early detection meaningfully changes outcomes, and is a smaller, more conservative list than some research panels. A Community Advisory Board, including representatives of historically underserved populations, will shape the consent, return of results, and equity provisions over the three year pilot.

The Generation Study: Britain at One Hundred Thousand

Across the Atlantic, the Generation Study, run by Genomics England in partnership with the NHS, is the largest single payer pilot in the world. Officially launched in October 2024, it aims to sequence the genomes of 100,000 newborns and screen for over 200 genetic conditions, with results returned through a National Genomic Research Library and the NHS specialist network. The study uses cord blood collected at birth and is scheduled to run through March 2027.

UK leadership has signaled that, contingent on results, a national rollout could begin in 2026 under a £650 million plan to offer whole genome sequencing to every newborn within a decade. The Generation Study expects roughly 1 percent of participants to receive a "condition suspected" result. The remaining 99 percent receive a "no condition suspected" outcome and no further action.

What is notable about the Generation Study is not the science, which closely tracks the American work, but the policy architecture. Britain is testing whether sequencing can be embedded inside a national universal health system that already delivers neonatal care from a single source. That is the regulatory and operational scenario American programs do not have. Watching the NHS rollout will be a critical reference point for whether BEACONS and its successors can succeed.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

BabySeq, BabySeq2, and the Unanticipated Risk Question

The longest running American program is the BabySeq Project, originally led by Robert Green and Alan Beggs at Brigham and Women’s, now in its second iteration as BabySeq2. The first BabySeq enrolled 159 infants and used exome sequencing rather than whole genome sequencing. Its most important finding was that 17 babies, or 10.7 percent, carried unanticipated monogenic risks that would not have been suspected from family history or clinical presentation. Several of those findings led to cancer risk reducing surgery in adult relatives identified through cascade testing.

BabySeq2, which began enrolling in January 2023 and is targeting more than 500 infants, was deliberately designed to over-represent Black and Hispanic families. More than 50 percent of the final cohort is expected to self-identify as Black or African American or Hispanic or Latino. That is a direct response to one of the field’s most serious problems: the overwhelming majority of variant interpretation reference data has come from European ancestry genomes, which both undercounts pathogenic variants in non-European populations and overgenerates false positives in the form of variants of uncertain significance.

BeginNGS: The Industrial Scale Validation

Rady Children’s Institute for Genomic Medicine in San Diego, led by Stephen Kingsmore, has taken the most aggressive approach. BeginNGS, short for Beginning of life Genome informed Newborn Screening, currently screens 53,575 variants across 412 severe childhood genetic diseases with at least 1,603 efficacious therapies. A retrospective evaluation in 618,290 anonymized subjects published in 2024 suggested adequate sensitivity and positive predictive value to justify prospective clinical studies, which are now underway in partnership with several hospital systems.

BeginNGS is designed for speed. Rady Children’s pioneered rapid whole genome sequencing for critically ill infants in the NICU, where a diagnosis in hours rather than weeks can change end of life decisions, surgical plans, and pharmacotherapy. Translating that speed into a population screening program is the next experiment.

The Hard Parts

The data are now strong enough that the bottleneck is no longer scientific. It is operational, ethical, and economic. Each of those deserves its own paragraph.

Operational capacity. The United States has roughly 5,000 board certified genetic counselors. A national newborn sequencing program at a 3 percent positive rate would generate more than 100,000 confirmatory consultations per year. Existing capacity cannot absorb that volume. Telehealth counseling, structured decision tools, and pediatrician training programs will all be necessary. Mass General Brigham has invested in a genomic counseling assistant designed to handle routine result disclosure, with human counselors stepping in for complex or distressing findings.

Ethical design. Newborns cannot consent. Their parents do, but a child’s adult onset risk information may someday be of interest to that child as an autonomous adult. The American College of Medical Genetics recommends against returning adult onset findings in pediatric sequencing unless they directly affect childhood medical care. GUARDIAN and BEACONS follow that principle. BabySeq has experimented with offering optional adult onset disclosure to parents, and the field is still working out where the right line sits. The Genetic Information Nondiscrimination Act of 2008 prohibits employment and most health insurance discrimination based on genetic information, but it does not cover life, disability, or long term care insurance. That gap is real and growing.

Equity. The interpretation burden falls hardest on babies of non-European ancestry, where reference data is thinner and variants of uncertain significance more common. BabySeq2 and BEACONS have built equity into their study design. The wider community must continue to invest in ancestry diverse reference databases or risk creating a precision medicine that works better for some children than others.

Economics. Current rapid whole genome sequencing clinical pricing ranges from roughly $5,000 to $10,000 per case once interpretation is included. At scale population sequencing could drop the marginal cost below $200 per genome over the next several years, with interpretation as the dominant remaining expense. The cost effectiveness math is favorable when one considers that early diagnosis of a single severe metabolic disorder can avert lifetime care costs in the millions, but the upfront capital and staffing investments are real. State Medicaid budgets, private insurers, and the federal Centers for Medicare and Medicaid Services have not yet aligned on reimbursement.

The Shape of the Next Five Years

The trajectory is clear. By 2030, several states are likely to offer optional whole genome sequencing as a standard add on to the existing newborn blood spot. By the early 2030s, depending on cost and counseling capacity, a federal Recommended Uniform Screening Panel revision could fold sequencing into the universal program. Britain may get there first, if the Generation Study reads out cleanly and the NHS rollout proceeds.

The deeper question is what a society does when every citizen begins life with a sequenced genome on file. The longevity medicine community, which has spent the last decade arguing for early detection biomarkers and precision interventions, is going to receive a generational data asset whether it is ready for it or not. The infrastructure of personalized prevention, from polygenic risk scores for cardiovascular disease to pharmacogenomics for psychiatric medications, becomes considerably more tractable when the underlying genome is already in the medical record.

The convergence is also moving faster than most clinicians realize. GUARDIAN has already enrolled past 25,000 babies. BEACONS will be operational across seven jurisdictions by the end of 2026. The Generation Study has cleared its first 500 samples and is scaling to 40 NHS hospital sites. BeginNGS has crossed half a million retrospective subjects. BabySeq2 will report its diverse cohort findings within 18 months. Five independent evidence streams, all pointing in the same direction.

What This Means For You

If you are an expectant parent, the most important practical point is that whole genome sequencing for newborns is not yet routine, but is increasingly available through research studies and through clinical channels at major academic centers. Ask your obstetrician or pediatrician whether your delivery hospital participates in GUARDIAN, BEACONS, BabySeq2, BeginNGS, or a similar program. Participation is voluntary and the consent process is rigorous. If your state is one of the seven selected for BEACONS, including Iowa, Minnesota, New York, Oregon, South Carolina, Texas, or Puerto Rico, ask specifically about that protocol.

If you are a parent of a child already diagnosed with a rare disease, the operational lessons from these programs are directly relevant. Centers running these protocols have built counseling, interpretation, and follow up infrastructure that is among the best in the country. Asking for a referral to one of these academic centers can shorten a diagnostic odyssey.

If you are a clinician, the field is moving faster than continuing medical education has caught up to. The American College of Medical Genetics, the American Academy of Pediatrics, and the National Society of Genetic Counselors all publish current practice guidance worth following. The Recommended Uniform Screening Panel is updated by the federal Advisory Committee on Heritable Disorders in Newborns and Children, and watching its review cycle is the best signal for when broader payer coverage will follow.

If you are a policy or business decision maker, the BEACONS sites and the NHS Generation Study are the operational case studies to track. They will define the implementation playbook for at least the next decade, and they will set the precedent for how sequencing data is governed, returned, and reimbursed inside public health systems.

If you are simply paying attention to the future of medicine, the takeaway is this. The era when every baby gets a genome is no longer a hypothetical. It is happening in 4,000 person increments, in seven American jurisdictions and across the NHS. The science has cleared the bar. The implementation is the work ahead, and it is the work that will shape how precision medicine is delivered for the rest of this century.

Sources

Ziegler A. et al. "Expanded Newborn Screening Using Genome Sequencing for Early Actionable Conditions." JAMA, October 24, 2024.

Columbia University Irving Medical Center. "In Pioneering Study, Gene Technology Outperforms Standard Newborn Screening Tests." October 2024.

Mass General Brigham. "First U.S. National Genomic Newborn Screening Initiative Launched with $14.4 Million NIH Award." Press release, 2025.

Ariadne Labs. "BEACONS Selects Seven Sites, Finalizes Gene List for Genomic Newborn Screening Study." January 28, 2026.

Genomics England and NHS England. The Generation Study. Newborn Genomes Programme overview and operational reports.

Genomes2People Research Program. The BabySeq Project and BabySeq2 study materials and publications, Brigham and Women’s Hospital.

Rady Children’s Institute for Genomic Medicine. BeginNGS retrospective evaluation in 618,290 subjects and prospective program design.

NIH Common Fund Venture Program. NBSxWGS (BEACONS) Initiative announcement, 2025.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.